Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Investing.com – Oppenheimer hat die Einstufung "Outperform" und das Kursziel von 205,00 US-Dollar für die Aktie von Biogen (NASDAQ: BIIB) nach der Veröffentlichung der Finanzergebnisse für das zweite ...

Discover key insights from Biogen's Q2 2025 earnings call: strong product launches, pipeline advancements, raised EPS guidance, and resilient MS ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...

Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen ...